Clinical Trial

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2025 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to evaluate the effectiveness of smallpox vaccination administered before the global eradication of smallpox against currently circulating mpox in the Democratic Republic of the Congo. The main question it aims to answer is: Is the smallpox vaccine experience protective against mpox infection ? Researchers will compare mpox test positive group and negative group to see if the smallpox vaccine can protect against mpox infection. Participants will * be included after informed consent, * respond the survey with structured questionnaire * and accept skin lesion and blood sampling.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-14.
Trial Details
NCT Number NCT06984705
Lead Sponsor Osaka Metropolitan University
Collaborators: Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
Conditions Mpox (Monkeypox)
Enrollment 144 participants
Start Date 2025-07-31
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-29